Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs
Jo Ishizawa(The University of Texas MD Anderson Cancer Center), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Graciela M. Nogueras‐González(The University of Texas MD Anderson Cancer Center), Marina Konopleva(Albert Einstein College of Medicine), Elisha J. Dettman(Eutropics Pharmaceuticals (United States)), Sharon Shacham(Roche (Switzerland)), Michael H. Cardone(The Ohio State University), Xuelin Huang(The University of Texas MD Anderson Cancer Center), William E. Pierceall(Bristol-Myers Squibb (Switzerland)), Dhruv Chachad(The University of Texas MD Anderson Cancer Center), Teresa McQueen(Leukemia Research Foundation), Kensuke Kojima(Kōchi University), Vivian Ruvolo(Hormel (United States))
Cited by 24
Related Papers
An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis.
|PubMed|2013|1.6k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|627